2017
Phenotypic spectrum of autosomal recessive congenital ichthyosis due to PNPLA1 mutation
Boyden LM, Craiglow BG, Hu RH, Zhou J, Browning J, Eichenfield L, Lim YL, Luu M, Randolph LM, Ginarte M, Fachal L, Rodriguez‐Pazos L, Vega A, Kramer D, Yosipovitch G, Vahidnezhad H, Youssefian L, Uitto J, Lifton RP, Paller AS, Milstone LM, Choate KA. Phenotypic spectrum of autosomal recessive congenital ichthyosis due to PNPLA1 mutation. British Journal Of Dermatology 2017, 177: 319-322. PMID: 28403545, PMCID: PMC5522355, DOI: 10.1111/bjd.15570.Peer-Reviewed Original Research
2016
Well-Differentiated Syringofibrocarcinoma in a Patient With Clouston Syndrome
Odell ID, Lilly E, Reeve K, Bosenberg MW, Milstone LM. Well-Differentiated Syringofibrocarcinoma in a Patient With Clouston Syndrome. JAMA Dermatology 2016, 152: 484. PMID: 26792110, DOI: 10.1001/jamadermatol.2015.4496.Peer-Reviewed Case Reports and Technical Notes
2013
Systemic retinoids in the management of ichthyoses and related skin types
DiGiovanna JJ, Mauro T, Milstone LM, Schmuth M, Toro JR. Systemic retinoids in the management of ichthyoses and related skin types. Dermatologic Therapy 2013, 26: 26-38. PMID: 23384018, PMCID: PMC3884695, DOI: 10.1111/j.1529-8019.2012.01527.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSkin typeHigh-dose vitaminMainstay of therapyTeratogenic side effectsSystemic retinoidsTerm retinoidsCareful surveillanceLimit toxicityEffective therapyDemonstrated efficacySide effectsMucous membranesVitamin ASevere ichthyosisSynthetic retinoidsEarly useRetinoidsTherapyVariety of agesSynthetic derivativesEfficacyTreatmentLimited usefulnessAcetretinEtretinate